Proactiveinvestors United Kingdom - Pharma & Biotech RSS feed Proactiveinvestors United Kingdom - Pharma & Biotech feed en Thu, 22 Feb 2018 19:08:28 +0000 Genera CMS Sareum Holdings: Pre-clinical data for new cancer combination to be presented to US peers Thu, 22 Feb 2018 13:20:00 +0000 National Milk Records ups growth ante with added value tech Thu, 22 Feb 2018 11:21:00 +0000 Collagen Solutions soars after positive outcome to epic ChondroMimetic implants study Wed, 21 Feb 2018 13:25:00 +0000 SkinBioTherapeutics on track to start first human study for its cosmetic application this year Wed, 21 Feb 2018 09:22:00 +0000 JPMorgan Cazenove provides wrong medicine for Shire, downgrading its rating to ‘neutral’ Tue, 20 Feb 2018 11:32:00 +0000 Hikma shares rise as it appoints former Teva executive as CEO Tue, 20 Feb 2018 09:58:00 +0000 Futura Medical welcomes former Shield Therapeutics FD to the board Tue, 20 Feb 2018 08:04:00 +0000 Concepta launches myLotus app in China Tue, 20 Feb 2018 07:20:00 +0000 WideCells Group launches Wideacademy platform and appoints new non-executive director Mon, 19 Feb 2018 08:12:00 +0000 Faron Pharmaceuticals raises £15mln to establish network for Traumakine launch Fri, 16 Feb 2018 16:00:00 +0000 Scancell to work with Dutch firm on first product for Moditope cancer immuno-therapy platform Thu, 15 Feb 2018 15:00:00 +0000 Indivior increases provisions for litigation matters, but 2017 revenue, profit both rise Thu, 15 Feb 2018 11:08:00 +0000 Oxford BioMedica’s shares shares rise after unveiling US$100mln agreement with Bioverativ Thu, 15 Feb 2018 10:00:00 +0000 Concepta signs marketing deal with Chinese firm which provides free WiFi in maternity hospitals Thu, 15 Feb 2018 08:15:00 +0000 Collagen Solutions re-jigs China distribution arrangements Thu, 15 Feb 2018 08:15:00 +0000 ConvaTec 2017 profits fall on supply issues and lower sales of new products Thu, 15 Feb 2018 08:13:00 +0000 NetScientific announces first sale of point-of-care test from portfolio company Thu, 15 Feb 2018 07:30:00 +0000 Shire shares hit reverse gear after it cautions on earnings Wed, 14 Feb 2018 13:38:00 +0000 MaxCyte defying the odds as it gears up for pivotal year Wed, 14 Feb 2018 11:52:00 +0000 Midatech Pharma trading in line with forecasts with focus turning to clinical trials Wed, 14 Feb 2018 07:41:00 +0000 ReNeuron's CTX cells play a part in positive artificial nerve tissue study Tue, 13 Feb 2018 14:10:00 +0000 National Milk Records boosted by dairy price recovery Tue, 13 Feb 2018 09:20:00 +0000 MaxCyte appoints biotech pioneer as independent director Tue, 13 Feb 2018 08:04:00 +0000 Allergy Therapeutics' grass pollen study running ahead of schedule Mon, 12 Feb 2018 13:39:00 +0000 Scancell drug receives positive write-up in leading journal as company updates on survival data Mon, 12 Feb 2018 11:50:00 +0000 GlaxoSmithKline winning over City number crunchers Fri, 09 Feb 2018 13:37:00 +0000 NetScientific highlights promising report on portfolio company Vortex BioSciences' cancer technology Fri, 09 Feb 2018 08:12:00 +0000 Scancell to receive patent protection for key cancer platform Fri, 09 Feb 2018 07:30:00 +0000 Abzena a play on the biologics revolution, says City broker Thu, 08 Feb 2018 13:14:00 +0000 Indivior files another lawsuit in latest bid to stop copycats of its best-selling addiction drug Thu, 08 Feb 2018 09:15:00 +0000 Motif Bio to present at prestigious infectious diseases conference Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), caught up with Proactive's Andrew Scott following the news that three iclaprim abstracts have been accepted for presentation at the upcoming 28th European Congress of Clinical Microbiology and Infectious Diseases in Madrid this April.

ECCMID brings together leading experts in the infectious diseases, infection control and clinical microbiology sectors.

Lumsden says it's an important arena to showcase Motif Bio's iclaprim data.

Wed, 21 Feb 2018 19:44:00 +0000
A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine results in Q2 Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products.

Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment for Acute Respiratory Distress Syndrome (ARDS).

Results from a phase III trial (INTEREST) are expected early in the spring, but Faron's keen to lay the groundwork for a product launch.

The money will also enable Faron to expand the scope of the upcoming phase I/IIb trial of immunotherapy cancer treatment Clevegen.

Wed, 21 Feb 2018 12:14:00 +0000
Collagen Solutions applies for European approval after successful ChondroMimetic study Jamal Rushdy, chief executive of Collagen Solutions PLC (LON:COS), discusses with Proactive the successful results from an eight-year extension clinical study of patients who received ChondroMimetic® implants for the repair of cartilage defects in the knee.

Rushdy says the positive results have now allowed them to submit an initial submission for a CE Mark.

Wed, 21 Feb 2018 08:06:00 +0000
Concepta PLC launches myLotus app for Android in China Erik Henau, chief executive of Concepta PLC (LON:CPT), discusses with Proactive the launch in China of the myLotus app.

The app accompanies their myLotus fertility aid.

Beijing Jiayou (AppInChina) will manage the app on Android systems throughout the country.

Through AppInChina, Concepta will market the app through the top 5 Chinese Android app stores.

Tue, 20 Feb 2018 11:56:00 +0000
WideCells Group strengthens board; launches Wideacademy Joao Andrade, chief executive of WideCells Group PLC (LON:WDC) as well as chairman Peter Presland discuss with Proactive's Andrew Scott the official launch of the first stage of Wideacademy -
the firm’s 100%-owned education and training division.

The newly launched platform provides content for both the public and medical professionals to raise the profile of stem cell technologies and support the development of the industry.

Mon, 19 Feb 2018 16:00:00 +0000
New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

Thu, 15 Feb 2018 12:38:00 +0000
National Milk Records' Andy Warne discusses operations and significant growth prospects Andy Warne, managing director of National Milk Records (NEX:NMR), tells Proactive they're a service provider in the diary industry.

''The basic services we provide are for farmers to become more efficient'', Warne says

''So it's the quality of the food they're producing and the volume of foo they're producing .... so our primary client is the dairy farmer but we also have a second business where we actually test milk on behalf of the milk processor''.

Profits in the half year to December more than doubled to £957,000 as conditions eased for the sector.

Wed, 14 Feb 2018 12:50:00 +0000
Critical year ahead of drug development for Midatech Pharma Jim Phillips, chief executive at Midatech Pharma Plc (LONMTPH, NASDAQ:MTP), updates Proactive's Andrew Scott on their three high-value, lead programmes progressing through pre-clinical and clinical development.

The key to each of those programmes is Midatech’s technology which allows it to precisely deploy drugs into the body.

Its two platforms – carbohydrate-coated gold nano-particles and its sustained release system – are about getting medicines to the right place in the right quantities at the right time.

Last month they secured a US$15mln, four-year senior loan facility to help bankroll the programmes.

Wed, 07 Feb 2018 12:40:00 +0000
ANGLE PLC opens up potential route to market for Parsortix platform Andrew Newland, chief executive of ANGLE PLC (LON:AGL), discusses with Proactive their significant new collaboration with healthcare giant Abbott Laboratories.

The two will be working on a metastatic breast cancer study.

Abbott will provide its proprietary PathVysion HER-2 DNA FISH Probe kits for ANGLE's ANG-002 US Food & Drug Administration (FDA) study for FISH (fluorescence in situ hybridization) analysis of circulating tumour cells (CTCs) in the form of a research grant.

FISH analysis, which is a form of investigation of the cancer cells used with solid tissue biopsy to help select treatment, is one of the exploratory end-points for ANGLE's FDA study in metastatic breast cancer

Tue, 06 Feb 2018 12:53:00 +0000
Amryt Pharma agrees Lojuxta distribution deal for Romania and Bulgaria Dave Allmond, chief commercial officer at Amryt Pharma PLC (LON:AMYT), discusses with Proactive their fourth distribution deal signed in three months for Lojuxta.

Lojuxta treats a very rare, life-threatening genetic condition which causes “bad cholesterol” to accumulate in the body. 

This latest agreement, covering Romania and Bulgaria, is with Romastru Trading, part of the Pharaon Healthcare Europe conglomerate.

Fri, 02 Feb 2018 15:50:00 +0000
Exciting start to 2018 for ImmuPharma with pivotal data 'weeks away' Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), caught up with Proactive's Andrew Scott to run through the latest on their Phase III Lupuzor study, results of which are due by the end of this quarter, as well as adding further detail to their ‘follow-up’ study which will allow eligible patients to continue to receive Lupuzor for another six months.

The results will be gathered as an ‘extension’ open label study – i.e. patients will know that they’re taking the drug – and will be independent of the original late-stage trial.

McCarthy also discusses the strong backing they received from existing and new institutional investors for their £10mln City fundraiser.

He says the cash will support future investment in the P140 peptide platform and will also be used to meet working capital requirements.

Fri, 02 Feb 2018 13:25:00 +0000
OptiBiotix Health 'in the strongest position they've ever been' Stephen O'Hara, chief executive of OptiBiotix Health plc (LON:OPTI) tells Proactive's Andrew Scott the big focus for them now is on the commercialisation of their technology across the company's platforms.

''2018 has started off very, very well'', O'Hara says.

He mentions they'll be presenting next week at ProBiota in Barcelona - a leading conference attended by the movers and shakers of the industry.

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics which can enhance the growth rate and health benefits of specific microbial species. In doing so they aid the efficacy of probiotic products.

''We've got a lot going on and a lot of relationships with partners that we haven't announced but are close to formalising deals on''.

Thu, 01 Feb 2018 12:56:00 +0000
Admedus Ltd moving up the value chain and preparing for 'pivotal' year Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), spoke to Proactive's Andrew Scott following the release of their quarterly update.

It's a big week for Admedus with the launch of both CardioCel in India and CardioCel 3D in North America.

CardioCel is the company’s flagship product and is becoming a surgeon-preferred biomaterial for heart valve repair surgeries.

Tue, 30 Jan 2018 22:28:00 +0000
Summit Therapeutics hugely excited after big DMD ‘breakthrough’ Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM,NASDAQ:SMMT), adds a bit of extra detail to their announcement this week around the interim data for their treatment for Duchenne Muscular Dystrophy (DMD).

The interim results for the PhaseOut study revealed a “statistically significant and meaningful” reduction in muscle damage in patients taking the company’s treatment, ezutromid.

''We're really pleased ... I wouldn't say we're surprised as we believe in the technology and we've been really hopeful that we're going to be able to make a huge impact on this really nasty disease that affects so many young men''.

Fri, 26 Jan 2018 13:30:00 +0000
ReNeuron pleased to secure podium presentation for stroke data at US conference Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) tells Proactive positive long-term data on their CTX cell therapy for stroke has been presented at the American Heart Association International Stroke Conference in Los Angeles.

Professor Keith Muir, of the Queen Elizabeth University Hospital, Glasgow and Principal Investigator for ReNeuron’s PISCES II study, told the audience that upper limb functional recovery was “durable and maintained” out to 12 months post-treatment.

Fri, 26 Jan 2018 12:48:00 +0000
Red letter day for Summit Therapeutics after positive interim ezutromid results Proactive Investors' editor Ian Lyall reports on the release this afternoon by Summit Therapeutics PLC (LON:SUMM,NASDAQ:SMMT) of encouraging data for its treatment for Duchenne Muscular Dystrophy (DMD).

The interim results for the PhaseOut study revealed a “statistically significant and meaningful” reduction in muscle damage in patients taking the company’s treatment, ezutromid.

Duchenne Muscular Dystrophy is a rare muscle-wasting disease that affects boys.

Thu, 25 Jan 2018 16:05:00 +0000
MaxCyte Inc gearing up for phase I study of potential cancer breakthrough Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer disease.

Doerfler adds they're in active discussions with the US Food & Drug Administration to begin the study later this year of MCY-M11, which is based on its CARMA technology.

Tue, 23 Jan 2018 11:53:00 +0000
Avacta enters significant partnership with OncoSec Medical Alastair smith, chief executive of Avacta Group Plc’s (LON:AVCT), tells Proactive that interest in their Affimer technology continues to grow following the announcement of another collaboration agreement - this time with OncoSec Medical Inc (NASDAQ:ONCS).

OncoSec has developed a gene delivery technology called ImmunoPulse which it wants to use to deliver Affimers - including Avacta’s PD-L1 inhibitor - into tumour cells and other tissues.

The companies plan to then demonstrate efficacy of the Affimers in a relevant in vivo tumour model.

Mon, 22 Jan 2018 10:45:00 +0000
ImmuPharma confident of topline results from Phase III Lupuzor trial this quarter Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), tells Proactive the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, their lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

He adds that 200 patients have now been successfully recruited and dosed, with top line results remaining on track to be reported in the first quarter of 2018.

Thu, 18 Jan 2018 15:55:00 +0000
Clinigen expecting good growth from all three operations in second half Clinigen Group PLC (LON:CLIN) chief executive Shaun Chilton discusses the group's half year trading update with Proactive's Andrew Scott.

Chilton says they're well positioned for another year of growth with trading at the halfway stage in line with expectations.

Revenues were up 28% year-on-year, although the figure was distorted by what are called ‘pass through costs’ associated with the unlicensed medicines it accesses on behalf of patients in need.

Wed, 17 Jan 2018 16:03:00 +0000
Scancell research collaboration deal with European biopharma BioNTech Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer. Scancell Co-Founder and Non-Executive Director Richard Goodfellow tells Proactive why the deal is significant for investors. The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors.

Fri, 12 Jan 2018 12:13:00 +0000
Rep Boost for Futura Medical's Erectile Dysfunction gel Sexual intimacy cures have been pedalled for centuries but science is now in the marketplace with, among others,  Futura Medical's (LON:FUM) MED2002 gel getting noticed in all the right places.The publication, The Journal of Sexual Medicine, is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel. CEO James Barder tells Proactive why he thinks MED2002 is superior to the two other main orally-taken competitors. James also updates us on the company's Clinical Development programme and progressing their Phase III pathway through 2018.

Thu, 04 Jan 2018 15:51:00 +0000
New loan for Midatech promises greater profitability Midatech Pharma Plc (LON:MTPH, NASDAQMTP) boss tells us how the company has secured a US$15mln, four-year senior loan facility that will be used to bankroll the clinical development of two promising cancer drug candidates. The funding has come via MidCap Financial, a middle market finance house, and Midtech has drawn down an initial US$7mln of the facility. CEO Jim Phillips tells Proactive what this will mean for Midatech during 2018 while giving us detail on new clinical trials on three different products.

Tue, 02 Jan 2018 14:48:00 +0000
WideCells strengthens management and advisory team CEO and Founder of WideCells Group (LON:WDC)  Joao Andrade tells Proactive how after recent product development/launches it's now time for the company to push through significant new appointments to make way for increased revenues during 2018.
WideCells is a worldwide healthcare services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment.
Joao explains how WideCells also has plans now to look at the next stage in developing their insurance products and well as giving updates on their significant new team-up with WG Partners.

Thu, 21 Dec 2017 10:42:00 +0000
Amryt appoints new Vice President CEO of Amryt Pharmaceutical  (LON:AMYT) Rory Nealon tells Proactive about the latest addition to the senior management team, their new Vice President, Patrick Jordan who will oversee their Lojuxta  business. Jordan is an 18-year veteran of the healthcare industry and has held senior roles at Pfizer and MSD (Merck & Co).
The company is a commercial-stage pharmaceutical company focussed on developing and producing treatments for rare and orphan diseases.
Its lead product, Lojuxta, treats a life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

Thu, 21 Dec 2017 09:26:00 +0000
Optibiotix Health eyes up future projects Per Rehne of Optibiotix Health (LON:OPTI) tells Proactive how the company's commercial journey through clinical trails, manufacturing and ultimately selling is a careful process of which he's been perfecting since he joined nine months ago. OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. Expanding the worldwide Optibiotix project portfolio is now the focus...hear how Per and the team intend to do just that.

Wed, 20 Dec 2017 08:40:00 +0000
ValiRx PLC gets go-ahead to expand and accelerate early-stage cancer study George Morris, chief operations officer at ValiRx Plc (LON:VAL) tells Proactive the've been given the go-ahead by regulators to expand and accelerate their early-stage cancer study.

The Medicines and Healthcare Regulator Agency and Research Ethics Committee are allowing them to substantially raise the dosing of VAL201, a treatment for metastatic prostate cancer and other solid tumours.

They'll be doing this to find the correct therapeutic levels of treatment to administer in order to try to stop the disease’s spread.

Tue, 19 Dec 2017 13:18:00 +0000
'Lots to look forward to' as ReNeuron gets go-ahead for phase IIb stroke trial Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE),  tells Proactive they've been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.

Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.

PISCES III – as this next study will be called – will be much bigger, recruiting 110 patients across 25 sites in the US.

The approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa.

Mon, 18 Dec 2017 12:06:00 +0000
NetScientific gaining critical mass with commercial ramp-up of portfolio Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), caught up with Proactive's Andrew Scott to update on developments within the IP commercialisation specialist's portfolio.

''All of our companies are game-changing and unique in their sectors'', Martelet says.

Most recently NetScientific announced the issue by the US Patent and Trademark Office of two new patents exclusively licensed to their portfolio company, Wanda.

The patents will significantly extend protection for the core technology used in Wanda's software application for remote health and patient management.

Thu, 14 Dec 2017 15:21:00 +0000
Cancer Research UK collaboration 'a stunning endorsement' for Scancell Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive Cancer Research UK is to fund and sponsor a Phase I/II clinical trial of their SCIB2 lung cancer vaccine.

Goodfellow says the tie-up is a significant endorsement of their  ImmunoBody platform – the underlying technology behind both SCIB1 and SCIB2 - which helps to prime a patient’s immune system to recognise and kill specific cancer cells.

Thu, 14 Dec 2017 13:21:00 +0000